Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma

[1] Kamisawa T(2016)Pancreatic cancer Lancet 388 73-85

[2] Wood LD(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-2921

[3] Itoi T(2020)Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future Lancet Oncol 21 e135-e145

[4] Takaori K(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[5] Rahib L(2020)Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma J Pancreatol 3 1-11

[6] Smith BD(2019)Adjuvant and neoadjuvant therapy for pancreatic cancer J Pancreatol 2 100-106

[7] Aizenberg R(2019)Prognostic factors for disease-free survival in patients with pancreatic ductal adenocarcinoma after surgery: a single center experience J Pancreatol 2 22-27

[8] Rosenzweig AB(1991)Frequency of abnormal expression of HLA-A, B, C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence Int J Cancer Suppl 6 155-162

[9] Fleshman JM(1987)Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface Nature 329 846-848

[10] Matrisian LM(1983)The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions J Immunol 131 611-616

[1] Kamisawa T(2016)Pancreatic cancer Lancet 388 73-85

[2] Wood LD(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-2921

[3] Itoi T(2020)Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future Lancet Oncol 21 e135-e145

[4] Takaori K(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[5] Rahib L(2020)Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma J Pancreatol 3 1-11

[6] Smith BD(2019)Adjuvant and neoadjuvant therapy for pancreatic cancer J Pancreatol 2 100-106

[7] Aizenberg R(2019)Prognostic factors for disease-free survival in patients with pancreatic ductal adenocarcinoma after surgery: a single center experience J Pancreatol 2 22-27

[8] Rosenzweig AB(1991)Frequency of abnormal expression of HLA-A, B, C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence Int J Cancer Suppl 6 155-162

[9] Fleshman JM(1987)Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface Nature 329 846-848

[10] Matrisian LM(1983)The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions J Immunol 131 611-616